By Allison Prang

A supplemental new drug application for a hepatitis C treatment from Gilead Sciences Inc. was approved by the U.S. Food and Drug Administration, Gilead said on Thursday.

Epclusa was approved for people who either weigh at least 17 kilograms or are at least 6 years old, Gilead said.

Gilead said the agency's approval is based on Phase II clinical trial data.

A child's dose of the treatment depends on how much they weigh and their liver's functioning, the company said.

Write to Allison Prang at allison.prang@wsj.com

(END) Dow Jones Newswires

March 19, 2020 15:33 ET (19:33 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gilead Sciences Charts.